Global Cell Lysis/Cell Fractionation Market

1 INTRODUCTION OF GLOBAL CELL LYSIS/CELL FRACTIONATIONMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CELL LYSIS/CELL FRACTIONATIONMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY TYPE OF CELL
5.1 Mammalian Cells
5.2 Microbial Cells
5.3 Other Cells

6 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY END USER
6.1 Research Laboratories and Institutes
6.2 Biopharmaceutical and Biotechnology Companies
6.3 Others

7 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY PRODUCT
7.1 Instruments
7.1.1 Sonicators
7.1.2 Homogenizers
7.1.3 Other Instruments
7.2 Consumables
7.2.1 Reagents and Kits
7.2.2 Beads
7.2.3 Disposables

8 GLOBAL CELL LYSIS/CELL FRACTIONATIONMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL CELL LYSIS/CELL FRACTIONATIONMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Thermo Fisher Scientific, Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Merck KGAA
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Bio-Rad Laboratories, Inc.
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Beckman Coulter, Inc. (A Subsidiary of Danaher Corporation)
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Becton, Dickinson and Company
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Cell Signaling Technology, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 MiltenyiBiotec
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd.)
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Qiagen N.V.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 Qsonica, LLC
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

11 Appendix
11.1 Related Reports